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Abstract
Background: Mouse double minute 2 (MDM2) and vascular endothelial growth factor (VEGF) are important
molecules involved in tumor progression. We researched potential inhibitors that simultaneously target MDM2
and VEGF. In our recent study involving the performance of high-throughput screening with a fluorescence
polarization assay, gossypol was identified as one of the top hits that inhibit protein-RNA binding activity.
Because MDM2 is an RNA-binding protein and its targets include VEGF mRNA, we investigated whether
gossypol has an inhibitory effect on MDM2-VEGF.
Methods: UV cross-linking and RNA binding assay, isothermal titration calorimetry assay, and ubiquitination assay
were performed to determine mechanisms by which gossypol functions as a dual inhibitor of MDM2 and VEGF. The
effect of gossypol on MDM2 and VEGF expression, cancer cell apoptosis, tumor growth and VEGF-mediated
angiogenesis were studied in vitro and in vivo in different human breast cancer models with a different p53 status.
Results: We observed that gossypol inhibited expression of both MDM2 and VEGF in human breast cancer cells with
either wild-type or mutant p53. A nechanistic study further demonstrated that, through disrupting the interaction
between MDM2 protein and VEGF mRNA, gossypol induced MDM2 self-ubiquitination and decreased VEGF translation
simultaneously, which resulted in both apoptosis and anti-angiogenesis effects.
In vitro, regardless of p53 status, gossypol induced cancer cell apoptosis. In nude mouse xenograft in vivo models,
gossypol suppressed tumor growth and VEGF-mediated angiogenesis.
Conclusion: Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer. Our study
reveals a novel mechanism by which gossypol functions as an anticancer agent. We believe that MDM2-VEGF targeting
represents a novel strategy for improving cancer outcome.
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Background
Mouse double minute 2 (MDM2) and vascular endothelial
growth factor (VEGF) are important molecules involved
in tumor progression. Increasingly there has been a broad
consensus that they should be used as key targets for drug
development. For example, selective small-molecule
MDM2 antagonist nutlin-3a has been discovered and is
under pre-clinical development [1]. The recombinant hu-
manized VEGF monoclonal antibody, bevacizumab, is
recommended by the National Comprehensive Cancer
Network (NCCN) guidelines for treatment of metastatic
cancer [2].
MDM2 is a multifunctional oncoprotein that is over-
expressed in a variety of human malignancies, including
breast cancer [3–9]. Recently published studies, including
ours, demonstrate that MDM2 is able to interact with spe-
cific RNA sequences or structures [10, 11]. The COOH-
terminal RING finger domain of MDM2 protein was
found to bind to the AU-rich sequence within the 3′un-
translated region (3′UTR) of VEGF mRNA, to stabilize
VEGF mRNA, and to increase its translation [12].
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MDM2 and VEGF have been considered as potential
cancer targets. Various MDM2 inhibitors have been
found to have anticancer activity. The most promising of
these is nutlin-3a. However, the majority of these inhibi-
tors exert their effects through restoring the p53 apoptotic
response [13]. But actually, more than 50% of all solid
tumors carry the p53 mutation [14], and there is a higher
incidence of p53 mutation or loss of p53 observed in
aggressive cancer [15]. Moreover, activated p53 in turn in-
duces MDM2 expression through the p53-MDM2 feed-
back loop. These compounds do not decrease expression
of MDM2 and may even increase it. In light of the p53-
independent mechanism through which MDM2 regulates
VEGF-mediated tumor angiogenesis, no significant VEGF
inhibition or anti-angiogenesis activity has been observed
after treatment with nutlin-3a [16].
Bevacizumab is the first Food and Drug Agency (FDA)-
approved anti-angiogenic drug for clinical use. There is
preliminary evidence of its efficacy when combined with
cytotoxic agents. However, even low-dose bevacizumab is
associated with increased risk of venous thromboembol-
ism and some patients with a clinical response to VEGF
blockade ultimately develop progressive disease [2].
Therefore, numerous studies remain committed to testing
novel anti-cancer drugs targeting MDM2 and VEGF, or
both simultaneously.
Gossypol, a polyphenol derived from cotton seeds, ex-
hibits potent anti-cancer activities and has completed phase
II clinical trials for treatment of human prostate cancer,
with promising initial results [17]. However, information
on its mechanism is still limited [18–21]. In our recent
study involving the performance of a high-throughput
screening (HTS) with fluorescence polarization (FP) assay
in four chemical libraries containing a total 141,394 known
reagents, drugs, and small-molecule compounds, gossypol
was identified as one of the top hits that inhibit protein-
RNA binding activity [22]. Because MDM2 is an RNA-
binding protein and its targets include VEGF mRNA, we
investigated whether gossypol has a similar inhibitory effect
on MDM2-VEGF. We found that gossypol is a potent
inhibitor of MDM2-VEGF. Through disrupting the inter-
action between MDM2 protein and VEGF mRNA, gossy-
pol induces MDM2 self-ubiquitination and decreases
VEGF translation simultaneously, which results in not only
cancer cell apoptosis but also suppression of tumor angio-
genesis. Our study helps to elucidate the mechanism by
which gossypol functions as an anticancer agent. We
believe that MDM2-VEGF targeting represents a novel
strategy for improving cancer outcome.
Methods
Cell lines and reagent
Five human breast cancer cell lines (MCF-7, ZR-75-1,
MDA-MB-231, MDA-MB-468 and T47D) were used in
this study. The first two have wild-type (wt) p53, while
the remaining three are p53-mutant. All five cell lines
were obtained from the China Center for Type Culture
Collection (CCTCC). The gossypol was purchased from
Sigma-Aldrich (St. Louis, MO, USA), and stock solution
was prepared at 10 mM in dimethyl sulfoxide (DMSO).
In vitro biological activity of gossypol was determined
after incubation at various concentrations (2.5, 5.0, 7.5,
and 10.0 μM) for different periods of time (2, 4, 8,
and 24 h). Equivalent concentrations of DMSO were
used as vehicle controls.
Plasmids and gene transfection
MDA-MB-468 cells with MDM2 knockdown or overex-
pression were described previously [23]. To determine
whether gossypol-induced ubiquitination of MDM2 re-
quired the intrinsic self-ubiquitination E3 ligase activity
of MDM2 itself, a QuickChange Site-Directed Mutagen-
esis Kit (Stratagene, La Jolla, CA, USA) was used to mu-
tate MDM2 464; this leads to cysteine being substituted
by alanine to generate the plasmid pCMV-MDM2
C464A, which exhibits loss of E3 ligase activity. MDM2
gene promoters 1 and 2 were cloned into the pGL3-Basic
vector to generate the MDM2 p1 and p2-Luciferase plas-
mids. MDA-MB-468 cells were transiently transfected
with these MDM2 promoter luciferase plasmids, treated
with gossypol and then prepared for testing the luciferase
activity of MDM2 promoter reporters using the Dual-
Luciferase Reporter Assay System (Promega, Madison,
WI, USA) according to the manufacturer’s instructions.
Quantitative RT-PCR
Quantitative RT-PCR was used to measure the expres-
sions of MDM2 and VEGF at mRNA level. The primer
sequences were as follows: MDM2 forward 5′-TGTTGGT
GCACAAAAAGACACTT-3′, MDM2 reverse 5′-GCAC
GCCAAACAAATCTCCTA-3′; VEGF forward 5′-GAT
GAAAGGCGGCATACGG-3′, VEGF reverse 5′-CAGG
GCTATTCTTCTTAGTGTGC-3′.
Western blot
The protein expression levels of MDM2, p53, VEGF,
caspase-3, cleaved caspase-3, and poly(ADP-ribose) poly-
merase (PARP) were analyzed by western blot. The
following antibodies were used: anti-MDM2 antibody
(1:1000; Sigma), anti-p53 antibody (1:1000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-VEGF anti-
body (1:200; Santa Cruz Biotechnology), anti-caspase-3
antibody (1:1000; Santa Cruz Biotechnology), anti-cleaved
caspase-3 p11 antibody (1:1000; Santa Cruz Biotechnol-
ogy), and anti-PARP antibody (1:1000; Cell Signaling,
Danvers, MA, USA).
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In vivo protein-RNA binding assay
To detect in vivo binding between MDM2 protein and
VEGF mRNA, VEGF mRNA was co-immunoprecipitated
with MDM2 antibody from whole-cell extracts by using a
previously described method [12]. The resulting RNA
was analyzed by quantitative RT-PCR using VEGF-
specific primers.
UV crosslinking and RNA binding assay
The DNA template for synthesis of the VEGF 3′UTR
probe was generated using the following sequence: 5′-
TAATACGAGTCACTATAGGGAAATTCTACATACTAA
ATCTCTCTCCTTTTTTAATTTTAATATTTG-3′. This
DNA fragment incorporated the T7 promoter sequence
(underlined). Internally labeled RNA probes were synthe-
sized by in vitro transcription with T7 polymerase (MAXI-
Script T7 RNA polymerase kit, Ambion) in the presence of
[α-32P] UTP (Amersham). GST-MDM2 protein was mixed
with 32P-labeled probes in the presence or absence of
gossypol. Then UV crosslinking of the RNA-protein com-
plexes formed was done using a 254-nm UV light source
set at 400,000 μJ/cm2. Finally, the UV-irradiated RNA-
protein complexes were treated with RNase T1, resolved by
10% SDS-PAGE gel and visualized by autoradiography.
Isothermal titration calorimetry (ITC) assay
The binding activity of gossypol to either MDM2 RING
protein or VEGF 3′UTR was examined by ITC assay.
The ITC assay was performed using the auto-iTC200 in-
strument (MicroCal, GE). MDM2 protein or VEGF 3′
UTR was loaded into a 96-well deep-well PP plate, and
then the compound was titrated stepwise into the pro-
tein or RNA sample cell using a syringe, for a total of 16
injections. The equilibrium time between two adjacent
injections was 210 s. The binding stoichiometry (n),
binding constant (Kd) and thermodynamic parameters
(ΔH and ΔS) were determined by fitting the titration
curve to a one-site binding mode, using the Origin soft-
ware provided by the manufacturer.
Polysome preparation and analysis
Polysome profiling was carried out as described previ-
ously [12]. Cells were incubated with 100 μg/ml cyclo-
heximide (CHX) for 15 minutes to arrest polyribosome
migration. The cells were then lysed to isolate cytoplas-
mic RNA in a buffer containing 20 mM Tris–HCl at
pH 8.0, 100 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100,
500 U/ml RNAsin and a cocktail of protease inhibitors.
The cell lysates were fractionated on a 15–45% (wt/vol) su-
crose gradient and centrifuged in a SW41Ti rotor at
39,000 rpm for 2 h. Fractions from each gradient tube were
collected by upward replacement, and absorption at optical
density (OD)254 was monitored using a fractionator. The
RNA in each fraction was extracted and subjected to quan-
titative RT-PCR.
Ubiquitination assay
Cells were treated with MG132 (30 μM) for 4 h before
collection. The cell pellet was lysed and incubated with
Ni2+-NTA beads (Qiagen, Valencia, CA, USA) at room
temperature for 4 h. The beads were then washed sequen-
tially for 5 minutes in each of the following buffers: buffer
A (6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4,
0.01 M Tris–HCl (pH 8.0), 5 mM imidazole, 10 mM β-
mercaptoethanol); buffer B (8 M urea, 0.1 M Na2HPO4/
NaH2PO4, 0.01 M Tris–HCl (pH 8.0), 10 mM β-
mercaptoethanol); buffer C (8 M urea, 0.1 M Na2HPO4/
NaH2PO4, 0.01 M Tris–HCl (pH 6.3), 10 mM β-
mercaptoethanol). This ubiquitinated product was finally
eluted with buffer D (200 mM imidazole, 0.15 M Tris–
HCl (pH 6.7), 30% glycerol, 0.72 M β-mercaptoethanol,
5% SDS) and analyzed by western blot using an anti-
ubiquitin antibody (Cell Signaling).
WST-1 cytotoxicity assay
The cytotoxic effect of gossypol was determined by WST-1
assay. Cells were cultured in 96-well plates along with dif-
ferent concentrations of gossypol for 24 h. WST-1 reagent
(25 μg/well; Roche) was then added and incubation contin-
ued for an additional 4 h. Following this, the OD of the
wells was read with a microplate reader (BioTek Instru-
ments, Winooski, VT, USA). Appropriate controls lacking
cells were included to determine background absorbance.
Flow cytometry
Flow cytometry was conducted to analyze the ability of
gossypol to induce apoptosis. Cells with or without gossy-
pol treatment were stained with fluorescein isothiocyanate
(FITC)-Annexin V and propidium iodide (BD Pharmin-
gen, San Diego, CA, USA). The stained cells were then de-
tected on a FACScan flow cytometer using the CellQuest
software (BD Biosciences, Mountain View, CA, USA).
Xenograft model
This study was approved by the Animal Care and Use
Committee of Huazhong University of Science and
Technology. Breast cancer xenograft models were estab-
lished. After 7 days, tumors were detected and gossypol
(dissolved in DMSO) was administrated intraperitoneally
at a dose of 10 mg/kg/day for 4 weeks. Control group re-
ceived control solution containing the same amount of
DMSO. Tumor growth and angiogenesis, as determined
by microvessel density (MVD), were evaluated for each
of these xenograft tumors.
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Statistical analysis
At least three independent experiments were performed.
All data were presented as mean ± SEM. Relative gene
expression data were analyzed using the 2 − ΔΔCT
method [24]. The statistical significance of differences
between groups was determined by one-way analysis of
variance (ANOVA) or by the nonparametric Kruskal-
Wallis test with the use of SPSS 13.0 software. All statis-
tical tests were two-sided. The significance level was set
at P < 0.05.
Results
Gossypol binds to MDM2 RING protein to disrupt its
interaction with VEGF 3′UTR, inhibiting the expression
of both MDM2 and VEGF
We first performed a protein-RNA binding assay to con-
firm whether gossypol could disrupt in vivo interaction
between MDM2 protein and VEGF mRNA. To determine
if this effect is dependent on p53, we compared the results
in the paired MCF-7 (p53-wt) and MDA-MB-468 (p53-
mutant) cells. Results from co-immunoprecipitation and
quantitative RT-PCR analysis showed that the MDM2
protein was able to bind VEGF mRNA; however, gossypol
disrupted their binding. As seen in Fig. 1a, in both MCF-7
and MDA-MB-468 cells, when precipitated with MDM2
antibody, the level of VEGF mRNA was significantly re-
duced after only 30 minutes of treatment with gossypol.
More specifically, UV crosslinking and RNA binding assay
showed that gossypol disrupted the binding of MDM2
RING protein to VEGF 3′UTR (Fig. 1b).
We then investigated the effect of gossypol on MDM2
and VEGF expression. We found that, regardless of the
p53 status, gossypol significantly inhibited the cellular




Fig. 1 Gossypol disrupts the binding of mouse double minute 2 (MDM2) RING protein to vascular endothelial growth factor (VEGF) 3′UTR to inhibit
the expression of MDM2 and VEGF in human breast cancer cell lines. a Protein-RNA binding assay to detect the effect of gossypol on the interaction
between MDM2 protein and VEGF mRNA. MCF-7 and MDA-MB-468 cells were treated with or without gossypol before harvesting. Following
co-immunoprecipitation with anti-MDM2, VEGF mRNA was detected by quantitative RT-PCR analysis. b UV crosslinking and RNA binding assay
for testing the effect of gossypol on the interaction between MDM2 RING protein and VEGF 3′UTR (labeled with 32P). Controls include VEGF
non-3′UTR probe, competitor (25-fold molar excess of unlabeled VEGF 3′UTR), and control small-molecule compound (no MDM2 inhibition).
c Western blot assays showing the dose–response and time-course of MDM2 and VEGF inhibition by gossypol. MCF-7 and MDA-MB-468 cells
were treated with different concentrations of gossypol for 24 h and 10 μM gossypol for different times, respectively. The expression of MDM2,
p53 and VEGF were detected by western blot. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as an internal control for equal
protein loading. d Comparison of the effects of gossypol (labeled MX11) and other compounds (labeled MX2, MX3, MX25 and MX28) on MDM2
and VEGF expression in MDA-MB-468 cells. e, f Determination of gossypol binding to MDM2 RING protein (e) or VEGF 3′UTR (f) as detected by
isothermal titration calorimetry. The upper box is raw heating power over time and the lower box is a fit of integrated energy values, normalized
for each injection
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inhibited expression of both MDM2 and VEGF in a
dose-dependent and time-dependent manner (Fig. 1c).
As controls, other compounds (labeled MX2, MX3,
MX25, and MX28) identified as the top hits that in-
hibit protein-RNA binding activity [22] did not simul-
taneously inhibit the expression of both MDM2 and
VEGF (Fig. 1d).
In addition, the ITC assay was performed to determine
whether gossypol binds to either MDM2 RING protein
or to VEGF 3′UTR to disrupt their interaction. The re-
sults showed that gossypol bound to the MDM2 RING
protein with a binding Kd value of 5.21 μM (Fig. 1e), but
not to the VEGF 3′UTR (Fig. 1f ). Therefore, gossypol
binds to MDM2 RING protein to disrupt its interaction
with VEGF 3′UTR and consequently inhibit the expres-
sion of both MDM2 and VEGF.
Gossypol induces MDM2 self-ubiquitination and protein-
degradation
We investigated further how MDM2 is inhibited by
gossypol. First, we performed quantitative RT-PCR for
the expression of MDM2 mRNA in gossypol-treated
cells. Gossypol did not inhibit MDM2 mRNA expres-
sion; instead, the MDM2 mRNA level actually increased
in the p53-wt cell line (Fig. 2a). This was consistent with
p53 activation as shown in Fig. 1c (the level of wt p53
was elevated in MCF-7 cells, while no significant effect
on mutant p53 was observed in MDA-MB-468 cells).
These results suggest that induction of MDM2 mRNA
by gossypol could be attributed to p53 activation. A
reporter assay in the p53-mutant MDA-MB-468 cell
line further confirmed that gossypol did not directly






Fig. 2 Gossypol induces mouse double minute 2 (MDM2) self-ubiquitination and protein-degradation. a MCF-7 and MDA-MB-468 cells were
treated with 10 μM gossypol for different time periods. The mRNA levels of MDM2 in tumor cells were determined by quantitative RT-PCR. Data
represent means ± SEM of three independent experiments normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). b MDA-MB-468
cells were transfected with MDM2 promoter luciferase plasmids (MDM2 p1-Luc or p2-Luc). Transfected cells were treated with increasing concentrations
of gossypol (2.5, 5.0, 7.5, and 10.0 μM) for 4 h and then analyzed by luciferase activity assay. c MDA-MB-468 cells were treated with or without 10 μM
gossypol for 4 h, followed by addition of 5 mg/ml actinomycin D. At different time points indicated after addition of the mRNA synthesis inhibitor
actinomycin D, the cells were harvested and the amount of MDM2 mRNA in the cells was detected by quantitative RT-PCR. d MDA-MB-468 cells
were treated with or without 10 μM gossypol for 8 h, and then their cytoplasmic lysates were fractionated on a sucrose gradient. RNA extracted from
each of the fractions was subjected to quantitative RT-PCR for quantitative analysis of the distribution of MDM2 mRNA. Data represent percentage of
the total amount of corresponding mRNA for each fraction. e MDA-MB-468 cells were treated with or without 10 μM gossypol for 4 h, followed by
addition of a protein synthesis inhibitor cycloheximide (CHX, 50 μg/ml). At different time points after CHX, cell lysates were prepared and analyzed by
western blot assay. f Ubiquitination assay in MDA-MB-468 cells for testing the effects of increasing concentrations of gossypol (2.5, 5.0, and 10.0 μM)
on ubiquitination of MDM2 in the presence or absence of VEGF 3′UTR. g MDA-MB-468 cells were treated with a proteasome inhibitor MG132 (30 μM)
for 4 h and subsequently with 10 μM gossypol for the indicated times. MDM2 ubiquitination was analyzed by immunoprecipitation-western blot assay.
h, i Immunoprecipitation-western blot assay to detect the effect of gossypol on the ubiquitination of mut-MDM2 C464A without E3 ligase activity.
VEGF vascular endothelial growth factor, wt wild-type
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and quantitative RT-PCR indicated that the stability
of MDM2 mRNA was not affected by gossypol (Fig. 2c).
Results from polyribosome profiling showed that gossypol
also did not regulate MDM2 translation (Fig. 2d). By
CHX pulse-chase assay, we found that MDM2 inhib-
ition by gossypol is through a protein-degradation
mechanism. The half-life of MDM2 protein in control
cells was more than 90 minutes, whereas gossypol
treatment decreased the half-life of MDM2 to less than
30 minutes (Fig. 2e).
It is well-known that MDM2 is ubiquitinated through
its own E3 ubiquitin ligase activity [25]. To further define
the mechanism by which gossypol promotes MDM2 pro-
tein degradation, the possibility that gossypol could induce
MDM2 self-ubiquitination was studied. As expected, gossy-
pol indeed induced ubiquitination of endogenous MDM2,
which was associated with VEGF 3′UTR (Fig. 2f, g). This
ubiquitination required the intrinsic self-ubiquitination E3
ligase activity of MDM2 itself. While gossypol induced
degradation and ubiquitination of wt MDM2, it was un-
able to induce degradation and ubiquitination of the
C464A mutant MDM2 that lacks E3 ubiquitin ligase ac-
tivity [26] (Fig. 2h, i). Therefore, gossypol inhibits
MDM2 expression through induction of MDM2 self-
ubiquitination and protein-degradation.
Gossypol decreases VEGF mRNA stability and thereby its
protein translation
When we evaluated the mechanism by which gossypol in-
hibits VEGF, we found that gossypol decreased VEGF
mRNA stability and thereby its protein translation. Gossy-
pol inhibited the VEGF mRNA level (Fig. 3a), which was
due to decreased mRNA stability (Fig. 3b). The half-life of
VEGF mRNA in MDA-MB-468 cells with gossypol treat-
ment (T1/2 = 38 ± 4 minutes) was significantly shorter than
that in untreated cells (T1/2 = 65 ± 7 minutes).
Because of decreased mRNA stability, we took steps to
investigate whether there also was a decrease in VEGF
protein synthesis. We performed linear sucrose-gradient
fractionation to assess the association between polyri-
bosomes and VEGF mRNA in MDA-MB-468 cells sub-
jected to gossypol treatment (Fig. 3c). We found that
VEGF mRNA shifted away from fractions enriched with
translating polyribosomes to fractions containing
translation-dormant complexes, which is indicative of
decreased translation. In contrast, gossypol had no effect
on the polyribosome profile of a control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA.
We also investigated whether inhibition of VEGF is
associated with MDM2. Gossypol inhibited VEGF in
control MDA-MB-468 cells but not in MDA-MB-468
A B
C D
Fig. 3 Gossypol decreases vascular endothelial growth factor (VEGF) mRNA stability and thereby its protein translation. a Quantitative RT-PCR for
VEGF mRNA expression in MCF-7 and MDA-MB-468 cells treated with 10 μM gossypol for different time periods. b Pulse-chase and quantitative
RT-PCR for the stability of VEGF mRNA in MDA-MB-468 cells treated with gossypol. c MDA-MB-468 cells were treated with or without 10 μM gossypol
for 8 h, and then their cytoplasmic lysates were fractionated on a sucrose gradient. RNA extracted from each of the fractions was subjected to
quantitative RT-PCR for quantitative analysis of the distribution of VEGF mRNA. Data represent percentage of the total amount of corresponding
mRNA for each fraction. d Western blot for expression of MDM2 and VEGF in MDA-MB-468 cells with MDM2 knockdown treated with indicated doses
of gossypol for 24 h
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cells with MDM2 knockdown (Fig. 3d), suggesting
that gossypol-mediated inhibition of VEGF is MDM2-
dependent.
Gossypol induces cancer cell apoptosis, dependent on
MDM2 inhibition
Next, we investigated the effects of gossypol on cancer
cell viability and apoptosis. We studied five human
breast cancer cell lines, with different p53 status (MCF-7
and ZR-75-1/p53-wt; MDA-MB-231, MDA-MB-468 and
T47D/p53-mutant). WST-1 assay showed that gossypol
exhibited significant cytotoxic activity against all these cell
lines (Fig. 4a).
To clarify whether the observed cell death was associ-
ated with induction of apoptosis, gossypol-treated cancer
cells were stained with Annexin V and quantitated by flow
cytometry. We found that gossypol-induced cell death was
indeed due to apoptosis. Gossypol induced apoptosis in
both wt and mutant p53-expressing cancer cells. As the
concentration of gossypol increased, the percentage of
apoptotic cells gradually increased. Correspondingly, cleav-
age of caspase-3 and PARP was detected by western blot-
ting after gossypol treatment (Fig. 4b).
We ask how critical oncoprotein MDM2 is to the
gossypol-induced cell apoptosis and death. Results as
shown in Fig. 4c indicated the importance of MDM2 in-
hibition. MDM2 siRNA or overexpression plasmid was
introduced into MDA-MB-468 cells. Cells with MDM2
knockdown or overexpression were less responsive to
gossypol-induced apoptotic effect than control cells.
Gossypol suppresses tumor growth and VEGF-mediated
angiogenesis in breast cancer xenograft models
Given the observed inhibitory effect of gossypol on
MDM2 and VEGF expression and cancer cell apoptosis,
we investigated whether gossypol could suppress tumor
growth and VEGF-mediated angiogenesis in a nude
mouse xenograft model. The breast cancer xenograft
model was established and treated by intraperitoneal in-
jections of gossypol. Tumor growth was continuously
monitored after treatment. Our results showed that in
both the MCF-7 and MDA-MB-468 xenograft models,
gossypol treatment significantly suppressed the growth of
the xenograft tumor. Compared to control tumors, gossy-
pol suppressed the xenograft tumor growth by 50.6% in
the MCF-7 xenograft model and by 53.0% in the MDA-
MB-468 xenograft model, respectively (Fig. 5a–c).
Upon processing tumor tissues, we found that gossy-
pol inhibited in vivo expression of MDM2 (Fig. 5d). In
addition, serum levels of VEGF in nude mice were mea-
sured by ELISA (Fig. 5e), providing further evidence for
the simultaneous inhibition of VEGF production by
gossypol. These results were consistent with those ob-
served in vitro in the breast cancer cell lines treated
with gossypol. Finally, the effect of gossypol on tumor
angiogenesis was evaluated by immunostaining for the
endothelial cell marker CD31. Positive staining was digit-
ally quantified and measured as MVD. Anti-angiogenesis
activity occurred following administration of gossypol.
Compared to control, there was a significant decrease in
CD31 staining (Fig. 5f). Accordingly, there was significant
A C
B
Fig. 4 Cytotoxic and apoptotic effects of gossypol on human breast cancer cells. Cells were treated with different concentrations of gossypol for
24 h for cell viability (a) and apoptosis assay (b). All assays were performed in triplicate. c MDA-MB-468 cells were transfected with mouse double
minute 2 (MDM2) siRNA or overexpression plasmid, and then the tumor cells were incubated with different concentrations of gossypol for 24 h
followed by cell apoptosis assay. Cells with MDM2 knockdown or overexpression were less responsive to gossypol-induced apoptotic effect than
control cells. GAPDH glyceraldehyde-3-phosphate dehydrogenase, PARP poly(ADP-ribose) polymerase
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suppression of MVD by 46.5% in the MCF-7 xenograft
model and by 51.2% in the MDA-MB-468 xenograft
model, respectively (Fig. 5g).
Discussion
There is evidence of the anti-cancer effects of gossypol
[17], and several studies have investigated the possible
molecular targets and mechanisms of action. For ex-
ample, gossypol has been identified as a Bcl-2 homology
3 (BH3)-mimetic, is able to bind to the BH3 domain of
Bcl-2 family members, and induces apoptosis [18]. In
addition, gossypol modulates the p53 [19], c-Myc [20]
and NF-κB [21] signaling pathways. In the present study,
we reported that gossypol is a potent inhibitor of
MDM2-VEGF. Through disrupting the molecular inter-
action between MDM2 protein and VEGF mRNA,
gossypol induces MDM2 self-ubiquitination and de-
creases VEGF translation, which results in both apop-
tosis and anti-angiogenesis effects.
Our study revealed a novel mechanism by which
gossypol functions as an anticancer agent. MDM2 and
VEGF are important molecules involved in tumor pro-
gression. MDM2 acts as an oncoprotein, while VEGF
plays crucial roles in tumor angiogenesis. For years, our
research has focused on the p53-independent activity
and mechanism of MDM2 in the regulation of VEGF
[12]. We also try to screen for potential inhibitors that
simultaneously target MDM2 and VEGF. Although cyto-
toxic drugs kill tumor cells, the plentiful blood supply to
the tumor can still allow residual tumor cells to continue
growing. Therefore, we believe that MDM2-VEGF dual-
targeting represents a novel cancer therapy strategy, not
only against cancer cells, but also against the tumor
microenvironment, especially tumor angiogenesis. This
will offer greater control on tumor growth.
For the first time, we described the inhibition of gossy-
pol on MDM2. Compared with other classical MDM2
inhibitors like nutlin-3a, gossypol is distinct in that it in-
hibits MDM2 and induces apoptosis in cancer cells with
a different p53 background. As mentioned, MDM2-p53
interaction inhibitors have several limitations. First,
these inhibitors exhibit effects only in cancer cells bear-
ing wild-type p53. Second, these inhibitors do not inhibit
MDM2, and expression of MDM2 can even be enhanced
through the p53-MDM2 feedback regulatory loop.
Third, these inhibitors would not be able to inhibit the
p53-independent activities of MDM2. Therefore, gossy-
pol should be particularly useful, especially for high-risk,
refractory cancer patients. Studies have shown that most
cancer patients, including breast cancer patients, do not
express wild-type p53 and mutations in p53 predict
worse prognosis and poor treatment outcome [27, 28].
Herein, a mechanistic study indicated that gossypol in-
duces MDM2 self-ubiquitination and protein degradation.
A
D E F G
B C
Fig. 5 Gossypol suppresses tumor growth and vascular endothelial growth factor (VEGF)-mediated angiogenesis in breast cancer xenograft models.
MCF-7 or MDA-MB-468 cells were subcutaneously implanted into nude mice and subsequently treated with gossypol. All mice underwent monitoring
of tumor growth. On day 42 post inoculation, serum samples and xenograft tumor tissues were obtained for MDM2 expression, VEGF production and
neovascularization analysis. a Xenograft tumor size. b Xenograft tumor weight on day 42. c Representative pictures from each group. d Expression of
Mouse double minute 2 (MDM2) in tumor tissues determined by western blot. e Concentrations of VEGF in the serum samples of nude mice
determined by ELISA. f Representative histology comparisons of tumor vessel content in xenografts from different treatment group, as
stained by CD31 immunohistochemistry (×200). g Positive immunostaining of CD31 was digitally quantified and measured as microvessel
density (MVD). Data represent mean ± SEM; n = 10 mice/group. *P < 0.05. GAPDH glyceraldehyde-3-phosphate dehydrogenase
Xiong et al. Breast Cancer Research  (2017) 19:27 Page 8 of 10
MDM2 has been well-characterized as a member of the
RING-finger-type family of E3 ubiquitin ligases. MDM2
regulates ubiquitination of not only p53 but also MDM2
itself [25]. The E3 ligase activity responsible for MDM2
self-ubiquitination is regulated by many cellular signaling
pathways and molecular events. Previous studies showed
that nucleic acids, such as polyA, polyG and certain
cellular small RNA, are able to bind to the RING do-
main of MDM2 and suppress its self-ubiquitination ac-
tivity [29, 30]. In the current study, the dissociation
between MDM2 protein and VEGF mRNA following
treatment with gossypol led not only to decreased
translation of VEGF mRNA but also to simultaneous
self-ubiquitination of MDM2 protein. These results pro-
vide a preliminary indication that binding of VEGF mRNA
to MDM2 protein may also suppress its self-ubiquitination
activity, which results in increased MDM2 protein stability
and expression. We have shown that, in response to hyp-
oxia, MDM2 protein is translocated from the nucleus to
the cytoplasm. In the cytoplasm, MDM2 binds to VEGF
mRNA and increases VEGF mRNA stability and transla-
tion [12]. On the other hand, further detailed studies are
required to give direct evidence that MDM2 and VEGF
are mutually regulated, and the E3 ubiquitin-ligase activity
of the MDM2 RING protein for self-ubiquitination is
negatively regulated by the binding of the VEGF mRNA.
VEGF is the most prominent angiogenic factor that
plays crucial roles in tumor angiogenesis. Gossypol has
previously been reported to modulate the VEGF signal-
ing pathway [31]. Gossypol inhibits VEGF expression in
human prostate cancer cells. Further, gossypol blocks
multiple steps in VEGF-activated biological events in
endothelial cells. For example, gossypol inhibits endothe-
lial cell viability, chemotactic motility, and microvessel
sprouting. Gossypol exerts its function through blockade
of the VEGF/VEGFR2 signal cascade in vascular endo-
thelial cells. In agreement, in this study, we also ob-
served that there was significant inhibition of VEGF in
human breast cancer following treatment with gossypol.
And besides that, importantly, we illuminated the mech-
anism by which gossypol inhibits production of VEGF
by cancer cells. Gossypol decreases VEGF mRNA stabil-
ity and thereby its protein translation. Our results help
to better understand the functional property of gossypol
in the VEGF signaling pathway.
Conclusions
In summary, gossypol is a dual inhibitor of MDM2 and
VEGF that disrupts the molecular interaction between
MDM2 protein and VEGF mRNA, induces MDM2 self-
ubiquitination and degradation, decreases VEGF mRNA
stability and protein translation simultaneously, and
therefore exerts anti-cancer effects through apoptotic
and anti-angiogenesis pathways in human breast cancer
in vitro and in vivo, regardless of the p53 status of the
cancer cells. We believe development of these MDM2-
VEGF inhibitors as potential anticancer drugs for clinical
use is worthwhile and represents a novel strategy for
improving cancer outcome.
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